ASX - By Stock
|
AM7 |
Re:
Ann: Drilling commenced at Bitterwasser Lithium in brines project
|
|
Lefevre
|
5 |
3.2K |
5 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
5
|
3.2K
|
5
|
|
IPOs
|
Biotech |
Re:
LTR Pharma - Viagra's worst nightmare
|
|
Lefevre
|
31 |
18K |
4 |
17/11/23 |
17/11/23 |
IPOs
|
31
|
18K
|
4
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Investor Presentation
|
|
Lefevre
|
100 |
40K |
10 |
17/11/23 |
17/11/23 |
ASX - By Stock
|
100
|
40K
|
10
|
|
ASX - By Stock
|
TX3 |
Re:
Ann: Drilling Update - Mt Hardy Base Metal Project
|
|
Lefevre
|
11 |
3.3K |
8 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
11
|
3.3K
|
8
|
|
ASX - By Stock
|
CC9 |
Re:
Prospectus
|
|
Lefevre
|
69 |
41K |
7 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
69
|
41K
|
7
|
|
ASX - By Stock
|
AM7 |
Re:
Ann: Withdrawal of resolution at 2023 Annual General Meeting
|
|
Lefevre
|
2 |
1.1K |
2 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
2
|
1.1K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
|
|
Lefevre
|
15 |
4.9K |
6 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
15
|
4.9K
|
6
|
|
ASX - By Stock
|
CC9 |
Re:
Prospectus
|
|
Lefevre
|
69 |
41K |
4 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
69
|
41K
|
4
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
|
|
Lefevre
|
15 |
4.9K |
7 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
15
|
4.9K
|
7
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Investor Presentation
|
|
Lefevre
|
100 |
40K |
2 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
100
|
40K
|
2
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Investor Presentation
|
|
Lefevre
|
100 |
40K |
9 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
100
|
40K
|
9
|
|
ASX - By Stock
|
LTP |
Re:
IPO - LTR Pharma Ltd - 11 December 2023 #
|
|
Lefevre
|
143 |
55K |
13 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
143
|
55K
|
13
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Investor Presentation
|
|
Lefevre
|
100 |
40K |
15 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
100
|
40K
|
15
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Research and Development Tax Offset $3m
|
|
Lefevre
|
6 |
1.7K |
3 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
6
|
1.7K
|
3
|
|
IPOs
|
|
Re:
Nico.lab Pre IPO
|
|
Lefevre
|
710 |
579K |
5 |
10/11/23 |
10/11/23 |
IPOs
|
710
|
579K
|
5
|
|
IPOs
|
Biotech |
Re:
LTR Pharma - Viagra's worst nightmare
|
|
Lefevre
|
31 |
18K |
8 |
09/11/23 |
09/11/23 |
IPOs
|
31
|
18K
|
8
|
|
ASX - By Stock
|
CC9 |
Re:
Ann: Drill Rig Arrives at Black Mountain
|
|
Lefevre
|
88 |
39K |
5 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
88
|
39K
|
5
|
|
ASX - By Stock
|
RRR |
Re:
Ann: Scale of Copper System Potential Emerging at Osprey
|
|
Lefevre
|
3 |
3.0K |
0 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
3
|
3.0K
|
0
|
|
ASX - By Stock
|
CC9 |
Re:
Prospectus
|
|
Lefevre
|
69 |
41K |
1 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
69
|
41K
|
1
|
|
ASX - By Stock
|
AM7 |
Re:
Ann: Capital raising targets drilling at lithium brine project
|
|
Lefevre
|
9 |
4.4K |
3 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
9
|
4.4K
|
3
|
|
IPOs
|
MWL |
Re:
IPO - Midwest Lithium Limited - 17 October 2023 #
|
|
Lefevre
|
10 |
7.4K |
2 |
06/11/23 |
06/11/23 |
IPOs
|
10
|
7.4K
|
2
|
|
ASX - By Stock
|
MAP |
Re:
Ann: Investor Presentation
|
|
Lefevre
|
3 |
1.9K |
4 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
3
|
1.9K
|
4
|
|
ASX - By Stock
|
MAP |
Re:
Ann: Investor Presentation
|
|
Lefevre
|
3 |
1.9K |
2 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
3
|
1.9K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
|
|
Lefevre
|
22 |
8.9K |
4 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
22
|
8.9K
|
4
|
|
ASX - By Stock
|
ERW |
Re:
AZS/WC8 and now into RDN/ERW
|
|
Lefevre
|
40 |
15K |
2 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
40
|
15K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
|
|
Lefevre
|
22 |
8.9K |
8 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
22
|
8.9K
|
8
|
|
ASX - By Stock
|
CAJ |
Re:
Enlitic IPO
|
|
Lefevre
|
8 |
4.1K |
2 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
8
|
4.1K
|
2
|
|
IPOs
|
Lithium |
Re:
Phoenix Water - PXW - Lithium - 100x
|
|
Lefevre
|
2.2K |
1.5M |
2 |
02/11/23 |
02/11/23 |
IPOs
|
2.2K
|
1.5M
|
2
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Breakthrough Results a Major Step Towards Commercialisation
|
|
Lefevre
|
74 |
27K |
1 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
74
|
27K
|
1
|
|
ASX - By Stock
|
ERW |
Re:
AZS/WC8 and now into RDN/ERW
|
|
Lefevre
|
40 |
15K |
2 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
40
|
15K
|
2
|
|
ASX - By Stock
|
ERW |
Re:
AZS/WC8 and now into RDN/ERW
|
|
Lefevre
|
40 |
15K |
4 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
40
|
15K
|
4
|
|
ASX - By Stock
|
CC9 |
Re:
Prospectus
|
|
Lefevre
|
69 |
41K |
2 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
69
|
41K
|
2
|
|
ASX - By Stock
|
ID8 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Lefevre
|
3 |
1.3K |
3 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
3
|
1.3K
|
3
|
|
ASX - By Stock
|
ID8 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Lefevre
|
3 |
1.3K |
3 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
3
|
1.3K
|
3
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Quarterly Activities Webinar Presentation - Sep 2023 Qtr
|
|
Lefevre
|
7 |
5.1K |
4 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
7
|
5.1K
|
4
|
|
IPOs
|
Biotech |
Re:
LTR Pharma - Viagra's worst nightmare
|
|
Lefevre
|
31 |
18K |
5 |
27/10/23 |
27/10/23 |
IPOs
|
31
|
18K
|
5
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Ground Reconnaissance Underway & T1 Placement Co
|
|
Lefevre
|
111 |
33K |
4 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
111
|
33K
|
4
|
|
ASX - By Stock
|
OCN |
Re:
Ann: Variation to Monaro Option Agreement
|
|
Lefevre
|
1 |
702 |
0 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
1
|
702
|
0
|
|
ASX - By Stock
|
CC9 |
Re:
Prospectus
|
|
Lefevre
|
69 |
41K |
3 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
69
|
41K
|
3
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Ground Reconnaissance Underway & T1 Placement Co
|
|
Lefevre
|
111 |
33K |
8 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
111
|
33K
|
8
|
|
ASX - By Stock
|
ERW |
Re:
Ann: Errawarra - Ground Reconnaissance Underway & T1 Placement Co
|
|
Lefevre
|
111 |
33K |
8 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
111
|
33K
|
8
|
|
ASX - By Stock
|
MAP |
Re:
Ann: Fully Underwritten A$20 million Entitlement Offer
|
|
Lefevre
|
7 |
3.1K |
5 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
7
|
3.1K
|
5
|
|
ASX - By Stock
|
MAP |
Re:
Ann: Fully Underwritten A$20 million Entitlement Offer
|
|
Lefevre
|
7 |
3.1K |
4 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
7
|
3.1K
|
4
|
|
ASX - By Stock
|
CLG |
Re:
Ann: Market Update
|
|
Lefevre
|
76 |
26K |
1 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
76
|
26K
|
1
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Notice of 2023 Annual General Meeting / Proxy Form
|
|
Lefevre
|
2 |
1.0K |
0 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
2
|
1.0K
|
0
|
|
ASX - By Stock
|
MAP |
Re:
Ann: Fully Underwritten A$20 million Entitlement Offer
|
|
Lefevre
|
7 |
3.1K |
2 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
7
|
3.1K
|
2
|
|
IPOs
|
Lithium |
Re:
Phoenix Water - PXW - Lithium - 100x
|
|
Lefevre
|
2.2K |
1.5M |
1 |
19/10/23 |
19/10/23 |
IPOs
|
2.2K
|
1.5M
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen September quarterly activity report & Appendix 4C
|
|
Lefevre
|
18 |
7.2K |
2 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
18
|
7.2K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
|
|
Lefevre
|
13 |
5.1K |
6 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
13
|
5.1K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen September quarterly activity report & Appendix 4C
|
|
Lefevre
|
18 |
7.2K |
5 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
18
|
7.2K
|
5
|
|